Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.
CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.
Pharma & Biotech
Pharma & Biotech
Why Norgine’s PEDMARQSI approval in Switzerland could reshape cisplatin ototoxicity management
Swissmedic approved PEDMARQSI for cisplatin-related hearing loss in children. Read why this could reshape paediatric oncology supportive care.
Pharma & Biotech
Can Assertio win market traction with convenience-led G-CSF dosing schedules?
Can same-day dosing of Rolvedon reduce burden in breast cancer care? Explore new trial data, regulatory risks, and clinical impact in this detailed analysis.